Mechanistic basis for the use of ketamine as an adjuvant to opioid analgesia – a pharmacokinetic drug-drug interaction study to define any clinically relevant drug to drug interaction between codeine and ketamine in healthy volunteers.

Flinders University- Department of Clinical Pharmacology0 个研究点目标入组 10 人开始时间: 2010年4月8日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Participant is capable of completing all participant assessments and complying with the study procedures, is able to give fully informed written consent, Normal performance status = Australian-modified Karnofsky performance stauts of 100.

•Any history of drug or alcohol abuse, any known allergy to either of the study medications,alcohol consumption during the trial period, on any regular or as needed medications including opioids and Non Steroidal Anti Inflammatory Drugs(NSAIDs),anaemia, renal dysfunction with creatinine clearance calculated as less than 25 ml/minute. Hepatic impairment defined as 2 times upper limit of mormal for 2 or more hepatic enzymes, International normalized ratio (INR >1.2 )– not treated with warfarin, documented respiratory failure induced by any opiate medication,recent seizures or history of uncontrolled epilepsy, medically assessed history of uncontrolled hypertension, cardiac arrhythmias, cardiac failure, ischaemic heart disease or history of cerebral vascular accident, cerebral trauma, intracerebral mass or previous intracerebral haemorrhage, currently taking monoamine oxidase inhibitors (MAOIs) or who have been taking non-reversible monoamine oxidase inhibitors within 4 weeks prior to study entry or reversible MAOIs within 5 days of study entry, history of increased intraocular pressure (e.g. glaucoma), schizophrenia, acute psychosis, acute intermittent porphyria, uncontrolled hyperthyroidism,women pregnant or lactating and if at risk of pregnancy must have appropriate and effective contraception in place.

发起方

Flinders University- Department of Clinical Pharmacology